Clinical Trial Update: A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures [Phase 3]

View source ↗

Summary

Phase 3 study to evaluate XEN1101 as adjunctive therapy for primary generalized tonic-clonic seizures is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Tonic-clonic Seizures

Drugs mentioned

• XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Primary Generalized Tonic-Clonic Seizures | Phase 3 | Status: RECRUITING